secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nautilus Biotechnology, Inc. (NAUT)
CIK:        0001808805
Form:       8-K
Filed at:   2022-03-31T23:59:59+00:00
Accession:  0001808805-22-000030
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nautilus Biotechnology appoints Karen Akinsanya, Schrödinger President, to Board
--------------------------------------------------------------------------------

- Appointment effective March 30, 2022; Akinsanya will serve as Class III director through 2024.
- Akinsanya is President of R&D, Therapeutics at Schrödinger and has 25+ years in drug discovery.
- Director compensation: $40,000/year plus initial option award of 105,998 shares ($370K grant date FV).
- She joins a board that includes leaders from genomics, cancer therapeutics, and tech (Illumina, Perceptive Advisors, etc.).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1808805/000180880522000030/0001808805-22-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1808805/000180880522000030/naut-20220330.htm
  HTML page:      https://secwatch.observer/filing/0001808805-22-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer